Long QT syndrome (LQTS) is a complication characterized by prolonged QT interval on electrodiagrams (ECGs). It occurs as a result of defects in the ion channels, which lead to delay in the time required by electrical systems to recharge after every heartbeat. Acquired long QT is caused due to sensitivity to some medications, whereas congenital long QT syndrome is caused due to abnormality in the gene code. Most probable symptoms associated with the disease include blacking out and seizures. In majority of the patients, the principal sign/manifestation of the infection shows up in the geriatric age. In addition, few risk factors associated with the syndrome include cardiovascular infection and diabetes. Additionally, fainting is the common indication of long QT condition. Fainting happens when the heart briefly thumps in a disorderly manner. Signs and symptoms associated with long QT condition may even occur during sleep. Prolonged long QT syndrome may lead to cardiac arrests, syncope, or sudden death.
COVID-19 Impact Analysis
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global long QT syndrome treatment market.
Top Impacting Factors
Factors such as rise in cases of cardiovascular illnesses & diabetes and increase in geriatric populace are the significant drivers that are anticipated to boost market development during the next five years.
Surge per capita national incomes and subsequent rise in disposable income that is incorporated into medical use coupled with expanding research and development and quick clinical trials by major players of the market are further fuelling the market development.
Additionally, government support for research and development, enormous patient populace, and favorable reimbursement policies drive the market growth.
However, factors such as lack of awareness for this condition, severe FDA regulations in North America, and significant expense associated with manufacturing & disposal of treatment of this syndrome are bound to hamper market development.
Key Market Trends
- U.S. is anticipated to dominate the worldwide long QT syndrome market, owing to high per capita income and expanding number of patients experiencing cardiovascular infections & diabetes due to changing lifestyles.
- Europe is the second biggest long QT syndrome market, owing to presence of advanced healthcare facilities and rising awareness in the region, which is trailed by Asia-Pacific.
-
- Asia-Pacific is witnessing quick market share growth due to the presence of newly industrialized economies and rising per capita income. Additionally, expanding pervasiveness of diabetes and rising geriatric populace are the variables further boosting the market development in the region.
- However, the Middle East and Africa are anticipated to witness lethargic growth in the worldwide long QT disorder market due to fragile economic conditions and severe government regulations in the region. Larger part of the market of this region is held by the Gulf countries, owing to rise of skilled professional and increase in foreign direct investment pertaining to healthcare sector.
Key Benefits of the Report
- This study presents the analytical depiction of the long QT syndrome treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the long QT syndrome treatment market share.
- The current market is quantitatively analyzed to highlight the long QT syndrome treatment growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the long QT syndrome treatment market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Long QT Syndrome Treatment Report
- Which are the leading players active in the long QT syndrome treatment market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the long QT syndrome treatment market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is long QT syndrome treatment?
- What is the long QT syndrome treatment market prediction in the future?
- What are the current trends and predicted trends?
Key Market Segments
- By Type
- Long QT syndrome type 1
- Long QT syndrome type 2
- Long QT syndrome type 3
- Others
- By Diagnosis
- Tests
- Electrocardiogram (ECG)
- Genetic testing
- Others
- By Treatment
- Medication
- Surgical procedures
- Others
- By End User
- Hospitals & clinics
- Diagnostic labs
- Research organizations
- Others
- By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Torrent Pharmaceuticals Limited
- Laboratory Corporation of America Holdings
- Invitae Corporation
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca
- Cipla Inc
- Asper Biogene
- Mylan N.V
- Zydus Pharmaceuticals, Inc
- Lupin Pharmaceuticals, Inc
- Boston Scientific Corporation
- GeneDx.
- Pfizer Inc.
- Aralez Pharmaceuticals Inc